Across TCGA pan-cancer cohorts, MIR1208 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR1208 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher MIR1208 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR1208 expression acts as an unfavorable survival marker.

PRAD and ESCA are the cancer types where MIR1208 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.197	0.775	.010	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR1208 tumor-vs-normal RNA expression · all MIR1208 data types